| 1. |
- Hammar, Mats, et al.
(författare)
-
Tibolone and low-dose continuous combined hormone treatment : Vaginal bleeding pattern, efficacy and tolerability
- 2007
-
Ingår i: British Journal of Obstetrics and Gynecology. - : Wiley. - 1470-0328 .- 1471-0528. ; 114:12, s. 1522-1529
-
Tidskriftsartikel (refereegranskat)abstract
- Objectives: The primary objective was to compare the vaginal bleeding pattern during administration of tibolone and low-dose continuous combined estradiol plus norethisterone acetate (E2/NETA). The secondary objectives were efficacy on vasomotor symptoms and vaginal atrophy. Design: A randomised, double-blind, double-dummy, group comparative intervention trial. Setting: Multicentre study executed in 32 centres in 7 European countries. Sample: Five hundred and seventy-two healthy symptomatic postmenopausal women, aged 45-65 years. Methods: Participants were randomised to receive 2.5 mg tibolone or 1 mg 17ß estradiol plus 0.5 mg norethisterone acetate (E 2/NETA) daily for 48 weeks. Main outcome measures: Prevalence of vaginal bleeding, hot flushes and adverse events. Results: The incidence of bleeding was significantly lower in the tibolone group during the first 3 months of treatment (18.3 versus 33.1%, P < 0.001) when compared with the E 2/NETA group. This effect on the bleeding pattern was sustained throughout the study, although reaching statistical significance again only in 7-9 months of treatment (11 versus 19%, P < 0.05). In both treatment groups, vasomotor symptoms and vaginal atrophy were significantly reduced to a similar extent when compared with baseline. The prevalence of breast pain/tenderness was significantly lower with tibolone compared with E2/NETA (3.2 versus 9.8%, P < 0.001). Conclusion: Tibolone reduces menopausal symptoms to a similar extent as conventional low-dose continuous combined hormone therapy but causes significant less vaginal bleeding in the first 3 months of treatment. This constitutes an important argument for woman adherence to therapy. © 2007 The Authors.
|
|
| 2. |
- Wolbers, F., et al.
(författare)
-
Microfluidic apoptosis chip for drug screening to improve and personalize cancer therapy
- 2008
-
Ingår i: 12th International Conference on Miniaturized Systems for Chemistry and Life Sciences - The Proceedings of MicroTAS 2008 Conference. - : Chemical and Biological Microsystems Society. ; , s. 549-551
-
Konferensbidrag (refereegranskat)abstract
- Currently, the knowledge on breast cancer treatment is increasing, however, there are still hardly any assays present to match patients to the right form of therapy to enhance the therapeutic effectiveness. Therefore a microfluidic device is developed to analyze the hormonal and chemosensitivity of first breast cancer cell lines (MCF-7) and in a later stage a patients' own tumor cells. The apoptotic inducers tumor necrosis factor-α, in combination with cycloheximide, and staurosporine stained MCF-7 cells positive for Annexin V and PI, and showed a decrease in area coverage as compared to untreated cells.
|
|
